PharmaEssentia’s Ropeg Expands Global ET Approvals While Europe Awaits Regulatory Clearance

Contributed by: Business Wire

Images

Dr. Jack Hwang, General Manager of PharmaEssentia Corp. and Representative of PharmaEssentia Corp. Taichung office.
Dr. Jack Hwang, General Manager of PharmaEssentia Corp. and Representative of PharmaEssentia Corp. Taichung office.
Business Wire embedded0

Tags

Science
Other Science
Biotechnology
Research
Pharmaceutical
Oncology
Health
Clinical Trials
PharmaEssentia Corporation

More Like This

PharmaEssentia founder and CEO, Dr. Ko-Chung Lin

From PV to ET to PMF, PharmaEssentia Has Come A Long Way in Fighting Diseases

Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH

Professor Heinz Gisslinger, MedUni Vienna/Austria (Fotocredit: IntMedCom)

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera to Be Presented at the American Society of Hematology (ASH) 65th Annual Meeting

Portrait: Dr. Rudolf Widmann | Member of the Board of Directors & Founder | AOP Health | Photocredit: AOP Health | Ospelt Photography

ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health